April 1, 2016
The Japan unit of Janssen Pharmaceuticals filed an application on March 31 seeking an additional indication for the anticancer agent Imbruvica (ibrutinib) for the treatment of relapsed or refractory mantle cell lymphoma (MCL), the company said. An oral once-daily Bruton’s...read more